Matt Holian is a partner in DLA Piper's Product Liability and Mass Tort practice group, which has been recognized by Legal 500 as Tier 1 since 2014 and by Chambers as Band 2 since 2015. Matt's practice involves the defense of pharmaceutical and medical device companies in a variety of cases, with an emphasis on serving as national counsel in complex, multi-jurisdictional product liability suits. Matt defends his clients from start to finish, beginning with litigation risk assessments before medications are approved and continuing through pretrial discovery, bellwether trials and, ultimately, resolution. Matt serves as the Co-Chair of the firm's Global Life Sciences Sector and as Co-Chair of its Pharmaceutical and Medical Device Product Liability sub-group.

Matt also has litigated cases involving alleged consumer fraud and other class actions, trade secret misappropriation and commercial disputes primarily relating to licensing agreements in the pharmaceutical and biotech industry.

In addition to his litigation practice, Matt also conducts compliance investigations and counsels clients regarding research and development issues (including defending hundreds of claims asserted by patients in clinical trials), Good Clinical Practices and Good Manufacturing Practices and other issues.